WARPTECHNEWS · LAB

Home AI Business Tech Archive

WARPTECH LAB NEWS

Warptech Lab News aggrega le notizie più rilevanti da oltre 700 fonti internazionali, con classificazione AI, TL;DR sintetici e timeline cluster su singole storie.

Navigazione

Home
Archivio
Editor's Brief
Cerca
Il tuo account
Newsletter tech/AI

Informazioni legali

Privacy Policy
Termini di servizio
Cookie Policy

© 2026 Sparktech S.R.L. — Tutti i diritti riservati. Sito gestito e manutenuto da Sparktech S.R.L.

Sede legale: Corso Libertà 55, 13100 Vercelli (VC), Italia · P.IVA / C.F. 02835910023 · Contatti: admin@warptechlab.com

Storia in 5 fonti

Ionis, AstraZeneca Stumble in ATTR-CM Trial as Rivals Stand to Gain - Ionis Pharmaceuticals (NASDAQ:IONS)

Ionis and AstraZeneca's Phase 3 ATTR-CM trial misses its primary goal, analyst says the outcome favors existing and next-gen therapies.

Raccontata da

biopharmadive.com

fiercepharma.com

Confronto fonti

5 prospettive sulla stessa storia

AI · summaries

benzinga.comStai leggendo8 h fa

Ionis, AstraZeneca Stumble in ATTR-CM Trial as Rivals Stand to Gain - Ionis Pharmaceuticals (NASDAQ:IONS)

Ionis and AstraZeneca's Phase 3 ATTR-CM trial misses its primary goal, analyst says the outcome favors existing and next-gen therapies.

Timeline cronologica

giovedì 9 luglio 2026·biopharmadive.com
AstraZeneca, Ionis drug fails big heart disease study in major setback
Eplontersen’s failure in transthyretin-mediated amyloidosis cardiomyopathy caught Wall Street analysts by surprise and boosted the outlook of rival drugs from Alnylam and…
giovedì 9 luglio 2026·endpoints.news
AstraZeneca sinks on unexpected heart drug trial failure
AstraZeneca shares sink up to 9% after Wainua misses cardiovascular endpoint in Phase 3 ATTR-CM trial with partner Ionis.

fiercepharma.com

1 g fa

AZ, Ionis shares tumble on ATTR-CM trial flop, but analyst flags over-reaction

The surprising failure of AstraZeneca and Ionis in a key phase 3 tria | The surprising failure of AstraZeneca and Ionis in a key phase 3 trial of Wainua in patients with ATTR-CM has sent the companies' shares tumbling,…

Leggi questa versione → originale

biopharmadive.com1 g fa

AstraZeneca, Ionis drug fails big heart disease study in major setback

Eplontersen’s failure in transthyretin-mediated amyloidosis cardiomyopathy caught Wall Street analysts by surprise and boosted the outlook of rival drugs from Alnylam and BridgeBio Pharma.

Leggi questa versione → originale

statnews.com1 g fa

AstraZeneca, Ionis report major trial failure with heart disease drug

AstraZeneca and Ionis reported a notable trial failure Thursday in a heart disease that's become an increasingly competitive market for drugmakers.

Leggi questa versione → originale

endpoints.news1 g fa

AstraZeneca sinks on unexpected heart drug trial failure

AstraZeneca shares sink up to 9% after Wainua misses cardiovascular endpoint in Phase 3 ATTR-CM trial with partner Ionis.

Leggi questa versione → originale

giovedì 9 luglio 2026·

statnews.com

AstraZeneca, Ionis report major trial failure with heart disease drug

AstraZeneca and Ionis reported a notable trial failure Thursday in a heart disease that's become an increasingly competitive market for drugmakers.

giovedì 9 luglio 2026·

benzinga.com

Why Is Ionis Pharmaceuticals, AstraZeneca Stock Tumbling Today? - AstraZeneca (NYSE:AZN), Ionis Pharmaceu

Ionis and AstraZeneca said Phase 3 eplontersen missed its primary ATTR-CM endpoint, while secondary measures and safety remained favorable.

giovedì 9 luglio 2026·

fiercepharma.com

AZ, Ionis shares tumble on ATTR-CM trial flop, but analyst flags over-reaction

The surprising failure of AstraZeneca and Ionis in a key phase 3 tria | The surprising failure of AstraZeneca and Ionis in a key phase 3 trial of Wainua in patients with ATTR-CM…

venerdì 10 luglio 2026·

benzinga.com

Ionis, AstraZeneca Stumble in ATTR-CM Trial as Rivals Stand to Gain - Ionis Pharmaceuticals (NASDAQ:IONS)

Ionis and AstraZeneca's Phase 3 ATTR-CM trial misses its primary goal, analyst says the outcome favors existing and next-gen therapies.